Lixte's LB100 Clinical Trials Validated by Nature, Offering New Treatment Paradigms for Cancer Patients.

Lixte Biotechnology Holdings (LIXT) announced that its clinical trials for ovarian and colorectal cancers using compound LB100 have been validated by Nature. The study led by Dr. Amir Jazaeri showed that mutations in PPP2R1A, targeted by LB100, improve survival outcomes in ovarian cancer patients. Lixte is conducting trials with GSK and Roche to test LB100's efficacy in combination with immunotherapies.

LIXTE Biotechnology Holdings, Inc. (LIXT) has received a significant boost as its clinical trials for ovarian and colorectal cancers using compound LB100 were validated by the prestigious medical journal Nature. The study, led by Dr. Amir Jazaeri, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, demonstrated that mutations in PPP2R1A, targeted by LB100, significantly improve survival outcomes in ovarian cancer patients [1].

The research, published in Nature, highlighted that inactivating mutations in PPP2R1A, which reduce the enzymatic activity of protein phosphatase 2A (PP2A), enhance the immune checkpoint response. This finding is particularly significant as it suggests that LB100, LIXTE's lead compound, could be a promising adjunct to immunotherapy for various cancer types.

LIXTE is currently conducting trials to test LB100's efficacy in combination with immunotherapies. In collaboration with GSK, LIXTE is testing LB100 in combination with dostarlimab (anti PD1) for ovarian clear cell carcinoma (OCCC). Additionally, in partnership with Roche, LIXTE is evaluating LB100 with atezolizumab (anti PDL1) for colon cancer patients at the Netherlands Cancer Institute [1].

Bas van der Baan, LIXTE's Chief Scientific Officer, expressed optimism about the findings, stating, "This work extends a body of pre-clinical evidence indicating that LB-100 is strongly synergistic with checkpoint immunotherapy in a range of cancer types. We look forward to the first results of our clinical studies in the second half of this year."

These developments underscore LIXTE's commitment to advancing its innovative approach to cancer treatment through the activation lethality paradigm, which focuses on enhancing the activity of existing therapies. The company's comprehensive patent portfolio and ongoing clinical trials in various cancer types, including ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma, reflect this dedication [1].

References:
[1] https://www.biospace.com/press-releases/new-clinical-findings-published-in-scientific-journal-nature-validate-lixtes-ongoing-ovarian-and-colorectal-cancer-trials
[2] https://www.curetoday.com/view/new-trials-target-brain-bladder-ovarian-and-other-cancers